Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFINITE: rAd-IFN + Celecoxib + Gemcitabine in Malignant Pleural Mesothelioma
NCT03710876Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jan 2019
- Primary completion
- Mar 2024
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of nadofaragene firadenovec in malignant pleural mesothelioma (MPM) (2 arms), sponsored by Ferring Pharmaceuticals. Primary endpoint: Overall Survival. Started Jan 2019; status: completed.
02
Drugs
nadofaragene firadenovec
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT03710876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03710876.